421
Views
11
CrossRef citations to date
0
Altmetric
Original Articles

Changes in medical and non-medical cannabis use among United States adults before and during the COVID-19 pandemic

ORCID Icon, ORCID Icon & ORCID Icon
Pages 321-327 | Received 14 May 2021, Accepted 05 Nov 2021, Published online: 07 Feb 2022
 

ABSTRACT

Background: During the SARS-CoV-2 pandemic, cannabis dispensaries in the United States (US) reported increased sales.

Objectives: This study assessed changes in cannabis use before to during the pandemic; it was hypothesized that cannabis use increased during the pandemic.

Methods: A US-based survey of adults assessed patterns of use before and during the pandemic. Participants recruited via social media from 8/2020 to 9/2020 self-reported medical and non-medical cannabis use. Use was categorized as ≤ monthly, weekly, and daily/almost daily; adjusted logistic regressions determined associations between cannabis use before the pandemic with change in frequency during the pandemic.

Results: Of 1,886 respondents (63% male),1,113 reported non-medical and 603 medical use of cannabis. Those reporting ≤monthly non-medical use before the pandemic had higher odds of increasing use during the pandemic than those using weekly before the pandemic (AOR 3.2 [95% CI 2.2–4.5]). Those reporting ≤ monthly and daily medical cannabis use before the pandemic had higher odds of increasing use during the pandemic than those using weekly before the pandemic (AOR 2.3 [95% 1.3, 3.9]; AOR 2.4 [95% CI 1.2, 5.1] respectively).

Conclusions: The most notable increases in cannabis use during the pandemic were among those who reported using cannabis least frequently before the pandemic (two to three times odds of increased use among ≤ monthly use compared to weekly). These findings have important implications for potential health consequences related to increased cannabis use both during and after the pandemic, even in populations thought to be protected by minimal use prior to the pandemic.

Disclosure statement

Dr. Cooper reports serving on the scientific advisory board of FSD Pharma. The submitted work is independent of this role. No other disclosures were reported.

Additional contributions

We thank Vincent Acebo, Manjot Aulakh, and Mary Olson for administrative Assistance

Additional information

Funding

This study was supported by the National Institute on Drug Abuse Grants DA047296, U01DA036267, and U24DA044554 DA047296 and the Semel Charitable Foundation.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 987.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.